Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

656 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts.
Armuzzi A, Felice C, Lubrano E, Cantini F, Castiglione F, Gionchetti P, Orlando A, Salvarani C, Scarpa R, Marchesoni A, Vecchi M, Olivieri I; Italian SpA-IBD Expert Panel Group. Armuzzi A, et al. Among authors: scarpa r. Dig Liver Dis. 2017 Dec;49(12):1298-1305. doi: 10.1016/j.dld.2017.06.004. Epub 2017 Jun 23. Dig Liver Dis. 2017. PMID: 28822731 Review.
Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs.
Atteno M, Peluso R, Costa L, Padula S, Iervolino S, Caso F, Sanduzzi A, Lubrano E, Del Puente A, Scarpa R. Atteno M, et al. Among authors: scarpa r. Clin Rheumatol. 2010 Apr;29(4):399-403. doi: 10.1007/s10067-009-1340-7. Clin Rheumatol. 2010. PMID: 20066450 Clinical Trial.
Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study.
Spadaro A, Punzi L, Marchesoni A, Lubrano E, Mathieu A, Cantini F, Olivieri I, Salvarani C, Scarpa R, Scrivo R, Ramonda R, Porru G, D'Angelo S, Catanoso M, Atteno M, Valesini G. Spadaro A, et al. Among authors: scarpa r. Rheumatology (Oxford). 2010 Jun;49(6):1107-11. doi: 10.1093/rheumatology/keq008. Epub 2010 Mar 11. Rheumatology (Oxford). 2010. PMID: 20223813
Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study.
Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP, Sardu C, Ujfalussy I, Scarpa R, Marchesoni A, Taylor WJ, Spadaro A, Fernàndez-Sueiro JL, Salvarani C, Kalden JR, Lubrano E, Carneiro S, Desiati F, Flynn JA, D'Angelo S, Vacca A, VAN Kuijk AW, Catanoso MG, Gruenke M, Peluso R, Parsons WJ, Ferrara N, Contu P, Helliwell PS, Mease PJ; GRAPPA 3PPsA Study Group. Cauli A, et al. Among authors: scarpa r. J Rheumatol. 2011 May;38(5):898-903. doi: 10.3899/jrheum.100857. Epub 2011 Feb 15. J Rheumatol. 2011. PMID: 21324965 Clinical Trial.
Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology.
Salvarani C, Pipitone N, Marchesoni A, Cantini F, Cauli A, Lubrano E, Punzi L, Scarpa R, Spadaro A, Matucci-Cerinic M, Olivieri I; Italian Society for Rheumatology. Salvarani C, et al. Among authors: scarpa r. Clin Exp Rheumatol. 2011 May-Jun;29(3 Suppl 66):S28-41. Epub 2011 Jul 26. Clin Exp Rheumatol. 2011. PMID: 21906425 Review.
Etanercept in spondyloarthropathies. Part I: current evidence of efficacy.
Palazzi C, D'Angelo S, Cantini F, Lubrano E, Marchesoni A, Mathieu A, Salvarani C, Scarpa R, Spadaro A, Olivieri I. Palazzi C, et al. Among authors: scarpa r. Clin Exp Rheumatol. 2011 Sep-Oct;29(5):858-64. Epub 2011 Oct 31. Clin Exp Rheumatol. 2011. PMID: 22041180 Review.
656 results